67 completed, 12 unknown, 7 not yet recruiting, 4 terminated. 92 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 92 | Completed 67, Unknown 12, Not yet recruiting 7, Terminated 4, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 3, Terminated 2, Unknown 1 |
Follow Drug Evaluation: new trials by email Literature Review of Drug Evaluation trials Research Report on Drug Evaluation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Bioequivalence and Safety Study of AJU-B718 and B718R in Healthy Adult Volunteers Under Fasting Conditions Test Drug, Reference Drug - Peripheral Arterial Disease | Phase 1 | Not yet recruiting | AJU Pharm Co., Ltd. | 40 | 2026-11-01 | 2026-10-28 |
| A Bioequivalence and Safety Study of AJU-C719 and C719R in Healthy Adult Volunteers Test Drug, Reference Drug - Hypertension | Phase 1 | Not yet recruiting | AJU Pharm Co., Ltd. | 60 | 2026-11-01 | 2026-10-28 |
| Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers Test Drug, Reference Drug - Hypercholerolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 61 | 2026-08-06 | 2026-09-09 |
| Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions Test Drug, Reference Drug - Moderate-to-severe Benign Prostatic Hyperplasia (BPH) | Phase 1 | Not yet recruiting | AJU Pharm Co., Ltd. | 36 | 2026-07-01 | 2026-06-11 |
| Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions Test Drug, Reference Drug - Moderate-to-severe Benign Prostatic Hyperplasia (BPH) | Phase 1 | Completed | AJU Pharm Co., Ltd. | 45 | 2026-06-27 | 2026-09-21 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 41 | 2026-06-11 | 2026-07-10 |
| Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer CKD-215, D215 - Ovarian Cancer | Phase 1 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 24 | 2026-06-01 | 2026-04-15 |
| A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting. Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg, Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg - Healthy Volunteers, Fasting Conditions | Phase 1 | Completed | LG Chem | 58 | 2026-01-09 | 2026-07-24 |
| A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male Participants GRT6019 - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Completed | Grünenthal GmbH | 18 | 2025-11-21 | 2026-02-13 |
| A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg, Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg - Fed Conditions, Healthy Volunteer | Phase 1 | Completed | LG Chem | 50 | 2025-09-29 | 2026-01-12 |
| A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults Comparator 1, Comparator 2, Test Drug - Type2 Diabetes Mellitus | Phase 1 | Not yet recruiting | AJU Pharm Co., Ltd. | 50 | 2025-08-01 | 2025-06-24 |
| A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study Comparator 1, Comparator 2, Test Drug - Type2 Diabetes Mellitus | Phase 1 | Not yet recruiting | AJU Pharm Co., Ltd. | 32 | 2025-08-01 | 2025-07-01 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults Test Drug, Reference Drug - Dyslipidemia | Phase 1 | Active not recruiting | AJU Pharm Co., Ltd. | 60 | 2025-05-24 | 2025-06-12 |
| A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A AD-120A, AD-120 - Gastroesophageal Reflux Disease (GERD) | Phase 1 | Not yet recruiting | Addpharma Inc. | 48 | 2025-04-21 | 2025-04-08 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 60 | 2025-03-29 | 2025-06-12 |
| A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability Test Drug (Eutropin Catridge, 48IU/Cartridge), Reference Drug (Eutropin, 4 IU/vial) - Healthy Volunteers | Phase 1 | Completed | LG Chem | 48 | 2025-01-13 | 2025-04-17 |
| A Study of TeriQ Patch in Healthy Adult Female Participants TeriQ Patch, Teribone Inj., Forteo Inj. - Osteoporosis | Phase 1 | Completed | QuadMedicine | 24 | 2024-10-25 | 2025-07-25 |
| Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease. AZD7798, [11C]AZ14132516 - Crohn Disease | Phase 1 | Completed | AstraZeneca | 9 | 2024-10-16 | 2026-04-14 |
| Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics Vamorolone, Midazolam - Drug Interaction | Phase 1 | Completed | Santhera Pharmaceuticals | 18 | 2024-08-13 | 2025-12-15 |
| A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379 CKD-379(Empagliflozin+sitagliptin+metformin) Test drug, CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug - Type 2 Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 28 | 2023-11-21 | 2024-01-12 |
Showing 20 of 92. Sign in to see all of them.
Dyslipidemias (5) · Hypertension (5) · Diabetes Mellitus, Type 2 (4) · Alzheimer Disease (3) · Gastroesophageal Reflux (3) · Leukemia, Myeloid, Acute (3) · Cardiovascular Diseases (2) · Cognitive Dysfunction (2) · Diabetic Neuropathies (2) · Hypercholesterolemia (2) · Hyperlipidemias (2) · Lymphoma, Non-Hodgkin (2) · Neuralgia (2) · Neuralgia, Postherpetic (2) · Osteoporosis (2)
AJU Pharm Co., Ltd. (13) · Chong Kun Dang Pharmaceutical (11) · Laboratorios Andromaco S.A. (9) · AstraZeneca (5) · Addpharma Inc. (4) · JW Pharmaceutical (4) · K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (4) · Cognition Therapeutics (3) · LG Chem (3) · Pfizer (3) · Boryung Pharmaceutical Co., Ltd (2) · Dong-A ST Co., Ltd. (2) · GL Pharm Tech Corporation (2) · Alopexx Vaccine, LLC (1) · Amgen (1)
South Korea (46) · United States (13) · Australia (7) · India (5) · Chile (4) · China (4) · Germany (2) · Spain (2) · Brazil (1) · Bulgaria (1) · Croatia (1) · Cyprus (1) · Finland (1) · Greece (1) · Indonesia (1)
Min-gul Kim (3) · James Zhang (2) · Min-Gul Kim, Ph.D. (2) · Seunghwan Lee, M.D.,Ph.D (2) · Sung Dae Kwon, M.D., Ph.D. (2) · Yook-Hwan Noh (2) · Alyssa Galley (1) · An-Hye Kim, M.D., PhD. (1) · Anthony Fiorino, MD, PhD (1) · Chang-Min Seong (1) · David Han, MD (1) · Hal Landy, MD (1)
PMID 12537512, PMID 15793367, PMID 15907596, PMID 17707845, PMID 20114004, PMID 25697420, PMID 32234755, PMID 33352008, PMID 33559354, PMID 37173791, PMID 38970537, PMID 39801777, PMID 40226119, PMID 41874840, PMID 7227774, PMID 7452494, PMID 7751691, PMID 7769277, PMID 9098665, PMID 9989342
R44DK107231 (1)